The use of erythropoiesis-stimulating agents (ESAs) has extensively improved morbidity, mortality, and kidney function and quality of life in these patients [8–11], although the target Hb level in patients with ND-CKD undergoing ESA treatment remains controversial [10, 12, 13]. Here, GSTM1 is linked to chronic kidney disease.